Page 434 - شرور شركات الأدوية

‫ﴍور ﴍﻛﺎت اﻷدوﻳﺔ‬

(93) Becker A, Dörter F, Eckhardt K, Viniol A, Baum E, Kochen MM, et al.
The association between a journal’s source of revenue and the drug recom-
mendations made in the articles it publishes. CMAJ. 2011 Feb 28 Available
from: http://www.cmaj.ca/content/early/2011/02/28/cmaj.100951.

(94) Smith R. Medical Journals Are an Extension of the Marketing Arm
of Pharmaceutical Companies. PLoS Med. 2005 May 17;2(5):e138.

(95) AUTH/2424/8/11 and AUTH/2425/8/11—General Practitioner v
Boehringer Ingelheim and Lilly. Available from: http://www.pmcpa.org.uk/
?q=node/998.

(96) Handel AE, Patel SV, Pakpoor J, Ebers GC, Goldacre B, Ram-
agopalan SV. High reprint orders in medical journals and pharmaceu-
tical industry funding: case-control study. BMJ. 2012 Jun 28;344(jun28
1):e4212-e4212.

(97) Jefferson T, Di Pietrantonj C, Debalini MG, Rivetti A, Demicheli V.
Relation of study quality, concordance, take home message, funding, and
impact in studies of influenza vaccines: systematic review. BMJ. 2009 Feb
12;338(feb12_2):b354.

(98) http://classic.the-scientist.com/blog/display/55679/.
(99) http://elsevier.com/wps/find/authored_newsitem.cws_home/
companynews05_01203.
(100) Bowman MA. The impact of drug company funding on the con-
tent of continuing medical education. Möbius: A Journal for Continuing
Education Professionals in Health Sciences. 1986 Jan 1;6(1):66–9.
(101) Bowman MA, Pearle DL. Changes in drug prescribing patterns
related to commercial company funding of continuing medical educa-
tion. Journal of Continuing Education in the Health Professions. 1988 Jan
1;8(1):13–20.

434